372 related articles for article (PubMed ID: 15853526)
1. Therapeutic potential of oxidant mechanisms in Alzheimer's disease.
Moreira PI; Smith MA; Zhu X; Santos MS; Oliveira CR; Perry G
Expert Rev Neurother; 2004 Nov; 4(6):995-1004. PubMed ID: 15853526
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic options in Alzheimer's disease.
Moreira PI; Zhu X; Nunomura A; Smith MA; Perry G
Expert Rev Neurother; 2006 Jun; 6(6):897-910. PubMed ID: 16784412
[TBL] [Abstract][Full Text] [Related]
3. Oxidative damage and Alzheimer's disease: are antioxidant therapies useful?
Moreira PI; Smith MA; Zhu X; Honda K; Lee HG; Aliev G; Perry G
Drug News Perspect; 2005; 18(1):13-9. PubMed ID: 15753972
[TBL] [Abstract][Full Text] [Related]
4. The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease.
Crouch PJ; White AR; Bush AI
FEBS J; 2007 Aug; 274(15):3775-83. PubMed ID: 17617225
[TBL] [Abstract][Full Text] [Related]
5. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity.
Varadarajan S; Yatin S; Aksenova M; Butterfield DA
J Struct Biol; 2000 Jun; 130(2-3):184-208. PubMed ID: 10940225
[TBL] [Abstract][Full Text] [Related]
6. Amyloid-beta, BACE, and oxidative stress in Alzheimer's disease, a commentary on "The different aggregation state of beta-amyloid 1-42 mediates different effects on oxidative stress, neurodegeneration and BACE-1 expression".
Lee HG; Perry G; Zhu X; Nunomura A; Smith MA
Free Radic Biol Med; 2006 Jul; 41(2):188-9. PubMed ID: 16814097
[No Abstract] [Full Text] [Related]
7. Amyloid inhibitors and Alzheimer's disease.
Xia W
Curr Opin Investig Drugs; 2003 Jan; 4(1):55-9. PubMed ID: 12625030
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
9. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the development of gamma-secretase inhibitors.
Josien H
Curr Opin Drug Discov Devel; 2002 Jul; 5(4):513-25. PubMed ID: 12197309
[TBL] [Abstract][Full Text] [Related]
11. Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment.
Wiley JC; Hudson M; Kanning KC; Schecterson LC; Bothwell M
J Neurochem; 2005 Sep; 94(5):1189-201. PubMed ID: 15992373
[TBL] [Abstract][Full Text] [Related]
12. The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease.
Blass JP; Gibson GE
Rev Neurol (Paris); 1991; 147(6-7):513-25. PubMed ID: 1962057
[TBL] [Abstract][Full Text] [Related]
13. Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE).
Onyango IG; Tuttle JB; Bennett JP
Mol Cell Neurosci; 2005 Jun; 29(2):333-43. PubMed ID: 15911356
[TBL] [Abstract][Full Text] [Related]
14. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease.
Mohmmad Abdul H; Sultana R; Keller JN; St Clair DK; Markesbery WR; Butterfield DA
J Neurochem; 2006 Mar; 96(5):1322-35. PubMed ID: 16478525
[TBL] [Abstract][Full Text] [Related]
15. Secretase inhibitors and modulators for Alzheimer's disease treatment.
Tomita T
Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
[TBL] [Abstract][Full Text] [Related]
16. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic treatments for Alzheimer's disease based on metal bioavailability.
Crouch PJ; Barnham KJ; Bush AI; White AR
Drug News Perspect; 2006 Oct; 19(8):469-74. PubMed ID: 17160147
[TBL] [Abstract][Full Text] [Related]
18. [Alzheimer's disease: from brain lesions to new drugs].
Forette F; Hauw JJ
Bull Acad Natl Med; 2008 Feb; 192(2):363-78; discussion 378-80. PubMed ID: 18819689
[TBL] [Abstract][Full Text] [Related]
19. Promising anti-Alzheimer's dimer bis(7)-tacrine reduces beta-amyloid generation by directly inhibiting BACE-1 activity.
Fu H; Li W; Luo J; Lee NT; Li M; Tsim KW; Pang Y; Youdim MB; Han Y
Biochem Biophys Res Commun; 2008 Feb; 366(3):631-6. PubMed ID: 18039469
[TBL] [Abstract][Full Text] [Related]
20. Oxidative stress: a bridge between Down's syndrome and Alzheimer's disease.
Zana M; Janka Z; Kálmán J
Neurobiol Aging; 2007 May; 28(5):648-76. PubMed ID: 16624449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
